Print

LEO Pharma Debuts Patient Assistance Program for Plaque Psoriasis Patients  
3/6/2012 9:33:14 AM

PARSIPPANY, N.J.--(BUSINESS WIRE)--LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, makers of the Taclonex® brand of products, is offering a Patient Assistance Program designed to provide medication to eligible uninsured patients who are suffering from plaque psoriasis. Taclonex® (calcipotriene and betamethasone dipropionate) Ointment, 0.005%/0.064% and Taclonex Scalp® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% are the only once-daily prescription, combination topical treatments for plaque psoriasis and scalp plaque psoriasis, respectively, on the U.S. market.
//-->